MedTrace Logo

Ionized Magnesium for Monitoring of Citrate-anticoagulated CVVHD

NCT04412980 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-11-24

No results posted yet for this study

Summary

It has been reported in several studies that ionized hypomagnesemia is associated with higher morbidity and mortality rates. During continuous renal replacement therapy with regional citrate anticoagulation (CRRT-RCA), the loss of magnesium has been reported to not be covered by magnesium concentration in ordinary dialysis fluid. This may lead to ionized hypomagnesemia. However the incidence of ionized hypomagnesemia in patients requiring CRRT-RCA remains unclear and need to be estimated to determine if ionized magnesium monitoring could be of interest. This study aim to assess the incidence of ionized hypomagnesemia induced by CRRT-RCA.

Conditions

  • Intensive Care Unit Syndrome

Sponsors & Collaborators

  • Novamedica Laboratories

    collaborator UNKNOWN

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Romaric Larcher, MD PhD · UH Montpellier

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2020-10-01
Completion
2020-11-23

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04412980 on ClinicalTrials.gov